ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain
September 13, 2018Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Admini -
FDA Grants Breakthrough Therapy Designation for CA-008
September 12, 2018Concentric Analgesics has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for CA-008 in post-surgical pain. CA-008 is a first-in-class non-opioid therapeutic that rapidly converts to capsaicin, a potent TRPV1-ago
Pharma Sources Insight January 2025
